GRP and prostate neoplasm: In an in vivo study with a prostate tumor-bearing SCID mouse model, the compound was demonstrated to significantly enhance the contrast of prostate cancer from the immediate nearby tissues in NIRF/MRI multi-modality imaging, via specific binding of bombesin to the GRP receptors.